172 related articles for article (PubMed ID: 415953)
1. [Costs and benefits of measles vaccination].
Ambrosch F; Wiedermann G; Harasek G
Fortschr Med; 1978 Feb; 96(8):409-14. PubMed ID: 415953
[TBL] [Abstract][Full Text] [Related]
2. Cost-benefit calculations of vaccinations against measles and mumps in Austria.
Wiedermann G; Ambrosch F
Dev Biol Stand; 1979; 43():273-7. PubMed ID: 118067
[TBL] [Abstract][Full Text] [Related]
3. Costs and benefits of measles and mumps immunization in Austria.
Wiedermann G; Ambrosch F
Bull World Health Organ; 1979; 57(4):625-9. PubMed ID: 118811
[TBL] [Abstract][Full Text] [Related]
4. Cost-benefit analysis of BCG-vaccination in Austria.
Ambrosch F; Klima H; Wiedermann G
Dev Biol Stand; 1979; 43():121-6. PubMed ID: 118066
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of vaccination policies. The case of measles].
Lafarge H; Levy E; Rey M
Rev Epidemiol Sante Publique; 1985; 33(3):182-93. PubMed ID: 4081224
[TBL] [Abstract][Full Text] [Related]
6. [Estimate of the cost/benefit ratio of measles vaccination].
Cárdenas Ayala VM; Ruiz Matus C; Cabrera Coello L; Montesano Castellanos R; Garrido Lozada MT; Olvera Castillo R; Díaz Ortega JL
Salud Publica Mex; 1989; 31(6):735-44. PubMed ID: 2516660
[TBL] [Abstract][Full Text] [Related]
7. [Health and economic benefits of mandatory regular vaccination in Slovakia. IV. Measles, rubella and mumps].
Hudecková H; Straka S; Avdicová M; Rusnáková S
Epidemiol Mikrobiol Imunol; 2001 Feb; 50(1):31-5. PubMed ID: 11233671
[TBL] [Abstract][Full Text] [Related]
8. Cost-benefit studies of vaccinations in Finland.
Elo O
Dev Biol Stand; 1979; 43():419-28. PubMed ID: 118069
[TBL] [Abstract][Full Text] [Related]
9. [Modern trends in vaccination policy: evaluation of benefits, risks and cost (author's transl)].
Wiedermann G
Wien Klin Wochenschr; 1979 Mar; 91(5):143-50. PubMed ID: 106558
[TBL] [Abstract][Full Text] [Related]
10. A benefit-cost analysis of a childhood varicella vaccination programme.
Preblud SR; Orenstein WA; Koplan JP; Bart KJ; Hinman AR
Postgrad Med J; 1985; 61 Suppl 4():17-22. PubMed ID: 3939152
[TBL] [Abstract][Full Text] [Related]
11. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of Haemophilus influenzae type b vaccination in Moscow, Russian Federation.
Platonov AE; Griffiths UK; Voeykova MV; Platonova OV; Shakhanina IL; Chistyakova GG; Robertson SE;
Vaccine; 2006 Mar; 24(13):2367-76. PubMed ID: 16413949
[TBL] [Abstract][Full Text] [Related]
13. Cost-benefit analysis of hepatitis a vaccination in Thailand.
Teppakdee A; Tangwitoon A; Khemasuwan D; Tangdhanakanond K; Suramaethakul N; Sriratanaban J; Poovorawan Y
Southeast Asian J Trop Med Public Health; 2002 Mar; 33(1):118-27. PubMed ID: 12118439
[TBL] [Abstract][Full Text] [Related]
14. [Are measles and mumps vaccinations worth while in Switzerland?].
Just M
Schweiz Med Wochenschr; 1978 Nov; 108(45):1763-8. PubMed ID: 100878
[TBL] [Abstract][Full Text] [Related]
15. Cost-benefit analysis of routine mumps and rubella vaccination for Israeli infants.
Berger SA; Ginsberg GM; Slater PE
Isr J Med Sci; 1990 Feb; 26(2):74-80. PubMed ID: 2108102
[TBL] [Abstract][Full Text] [Related]
16. Critical prevalence of antibodies minimizing vaccination costs for hepatitis A, hepatitis B, varicella, measles and tetanus in adults and adolescents in Catalonia, Spain.
Plans-Rubió P
Vaccine; 2004 Sep; 22(29-30):4002-13. PubMed ID: 15364450
[TBL] [Abstract][Full Text] [Related]
17. Health impact of measles vaccination in the United States.
Bloch AB; Orenstein WA; Stetler HC; Wassilak SG; Amler RW; Bart KJ; Kirby CD; Hinman AR
Pediatrics; 1985 Oct; 76(4):524-32. PubMed ID: 3931045
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives.
Navas E; Salleras L; Domínguez A; Ibáñez D; Prat A; Sentís J; Garrido P
Vaccine; 2007 Apr; 25(16):3233-9. PubMed ID: 17324489
[TBL] [Abstract][Full Text] [Related]
19. Measles epidemiology and outbreak response immunization in a rural community in Peru.
Sniadack DH; Moscoso B; Aguilar R; Heath J; Bellini W; Chiu MC
Bull World Health Organ; 1999; 77(7):545-52. PubMed ID: 10444877
[TBL] [Abstract][Full Text] [Related]
20. Measles control in developing and developed countries: the case for a two-dose policy.
Tulchinsky TH; Ginsberg GM; Abed Y; Angeles MT; Akukwe C; Bonn J
Bull World Health Organ; 1993; 71(1):93-103. PubMed ID: 8440043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
